Abstract Details

Title Leisure Time Physical Activity Is Associated with an Increased Risk of ALS

Topic Anterior Horn

Presentation(s) P05 - (-)

Poster/Presentation
Number 074

Objective

Background BACKGROUND: Ever since Lou Gehrig, a famous professional baseball player, died from ALS, it has been hypothesized that physical activity is a risk factor for developing ALS, fuelled by recent observations that professional soccer players and Gulf War veterans are at increased risk of ALS.

Design/Methods DESIGN/METHODS: 636 incident ALS patients and 2,166 controls filled in semi-structured questionnaires to obtain lifetime history of occupations, sports, and hobbies. All reported activities were assigned a metabolic equivalent score (MET) based on the Compendium of Physical Activities. The MET is a physiological measure expressing the energy cost of physical activities. Odds ratios for ALS with levels of cumulative occupational and leisure time physical activity were calculated, adjusted for gender, age, level of education, premorbid body mass index (BMI), current alcohol consumption and current smoking.

Results RESULTS: Higher levels of leisure time physical activity were associated with an increased risk of ALS (adjusted OR 1.08, 95% CI 1.02-1.14, P = 0.008). However, no association between ALS and occupational activity or vigorous physical activities, such as marathons and triathlons, was found. Moreover, dividing the cumulative measures of physical activity in quartiles showed no dose-response relationship between physical activity and ALS.

Conclusions CONCLUSIONS: The present population-based case-control study strengthens the hypothesis that physical activity itself is not causative per se, although higher levels of leisure time physical activity were associated with an increased risk of ALS, but rather that being athletic is a phenotypic expression of a genetic profile that increases the risk of ALS.

Authors/Disclosures
Meinie Seelen, MD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Marianne De Visser, MD, PhD (Academic Med Center)	Dr. De Visser has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. De Visser has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. De Visser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca.
Helenius J. Schelhaas, MD (Radboud University Medical Centrum Nijmegen)	No disclosure on file
Leonard van den Berg, MD (University Medical Centre Utrecht)	The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ferrrer. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. The institution of Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Projenx. Dr. Van den Berg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. The institution of Dr. Van den Berg has received research support from Netherlands ALS Foundation.
Jan H. Veldink, MD, PhD	The institution of Dr. Veldink has received research support from Biogen.
	No disclosure on file

��ɫ��

��ɫ��